相似文献
1
Topoisomerase I inhibitors and drug resistance.
Cytotechnology. 1998 Sep;27(1-3):149-64. doi: 10.1023/A:1008008719699.
2
DNA topoisomerase targeting drugs: mechanisms of action and perspectives.
Anticancer Drugs. 1997 Oct;8(9):811-22. doi: 10.1097/00001813-199710000-00001.
3
4
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Biochem Pharmacol. 1996 Apr 12;51(7):879-86. doi: 10.1016/0006-2952(95)02241-4.
5
DNA-topoisomerase inhibitors.
Curr Opin Oncol. 1993 Nov;5(6):1023-8.
6
Topoisomerase I in multiple drug resistance.
Cytotechnology. 1993;12(1-3):127-35. doi: 10.1007/BF00744661.
7
High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.
Cell Prolif. 2001 Aug;34(4):243-52. doi: 10.1046/j.0960-7722.2001.00214.x.
8
DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. doi: 10.2174/156800910793605785.
9
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048223. doi: 10.1128/aac.00482-23. Epub 2023 Sep 19.
10
Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252.
引用本文的文献
1
Structural modifications of berberine and their binding effects towards polymorphic deoxyribonucleic acid structures: A review.
Front Pharmacol. 2022 Aug 9;13:940282. doi: 10.3389/fphar.2022.940282. eCollection 2022.
2
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Cancers (Basel). 2021 Mar 20;13(6):1420. doi: 10.3390/cancers13061420.
3
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.
J Nanobiotechnology. 2020 Jan 2;18(1):1. doi: 10.1186/s12951-019-0560-5.
4
Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model.
Cell Death Dis. 2019 Jun 13;10(6):467. doi: 10.1038/s41419-019-1690-2.
5
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.
Invest New Drugs. 2013 Apr;31(2):320-32. doi: 10.1007/s10637-012-9868-9. Epub 2012 Aug 17.
6
High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.
Cell Prolif. 2001 Aug;34(4):243-52. doi: 10.1046/j.0960-7722.2001.00214.x.
本文引用的文献
1
Topoisomerase I inhibitors: review and update.
Ann Oncol. 1997 Sep;8(9):837-55. doi: 10.1023/a:1008270717294.
2
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Cancer Chemother Pharmacol. 1997;40(5):433-8. doi: 10.1007/s002800050682.
3
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Mol Pharmacol. 1997 Jul;52(1):82-7. doi: 10.1124/mol.52.1.82.
4
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
J Med Chem. 1997 Jun 20;40(13):2040-6. doi: 10.1021/jm970044r.
5
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
J Med Chem. 1997 Jun 6;40(12):1919-29. doi: 10.1021/jm970004n.
6
Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.
J Comput Aided Mol Des. 1997 Jan;11(1):71-8. doi: 10.1023/a:1008027528218.
7
Analysis of expression and function of topoisomerase I and II during meiosis in male mice.
Mol Reprod Dev. 1997 Apr;46(4):489-98. doi: 10.1002/(SICI)1098-2795(199704)46:4<489::AID-MRD7>3.0.CO;2-K.
8
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Br J Cancer. 1997;75(6):869-77. doi: 10.1038/bjc.1997.154.
9
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.
Cancer Chemother Pharmacol. 1997;39(5):467-72. doi: 10.1007/s002800050600.
10
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
Cancer Chemother Pharmacol. 1997;39(5):417-23. doi: 10.1007/s002800050592.
Zotero 插件